tyramine has been researched along with rasagiline in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Finberg, JP; Youdim, MB | 2 |
| Finberg, JP; Tenne, M; Youdim, MB | 1 |
| Blindauer, K; deMarcaida, JA; Fahn, S; Kieburtz, K; Schwid, SR; Shoulson, I; Stern, M; White, WB | 1 |
| Salzman, P; Schwid, SR; White, WB | 1 |
| Isaacson, SH | 1 |
| Adar, L; Goren, T; Sasson, N; Weiss, YM | 1 |
| Chen, JJ; Wilkinson, JR | 1 |
2 review(s) available for tyramine and rasagiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Topics: Antiparkinson Agents; Brain; Dietary Proteins; Dose-Response Relationship, Drug; Food-Drug Interactions; Humans; Hypertension; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Safety; Risk Assessment; Risk Factors; Treatment Outcome; Tyramine | 2012 |
3 trial(s) available for tyramine and rasagiline
| Article | Year |
|---|---|
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Food-Drug Interactions; Heart Rate; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Risk Factors; Tyramine | 2006 |
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Topics: Aged; Antihypertensive Agents; Antiparkinson Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Food; Humans; Hypertension; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Postprandial Period; Supine Position; Telephone; Tyramine | 2008 |
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Topics: Adult; Aged; Algorithms; Contraindications; Diet; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Humans; Hypertension; Indans; Isoenzymes; Male; Methoxyhydroxyphenylglycol; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tyramine; United States | 2010 |
4 other study(ies) available for tyramine and rasagiline
| Article | Year |
|---|---|
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine | 1987 |
Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.
Topics: Amines; Animals; Blood Pressure; Brain; Cats; Clorgyline; Female; Indans; Liver; Male; Monoamine Oxidase Inhibitors; Nictitating Membrane; Phenethylamines; Selegiline; Sympathetic Nervous System; Tyramine | 1985 |
Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.
Topics: Animals; Blood Pressure; Clorgyline; In Vitro Techniques; Indans; Indenes; Male; Metaraminol; Monoamine Oxidase Inhibitors; Neurons; Octopamine; Rats; Selegiline; Tyramine; Vas Deferens | 1981 |
Selective MAO-B inhibitors have low potential for the tyramine effect.
Topics: Blood Pressure; Heart Rate; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Tyramine | 2010 |